Rhabdomyosarcoma 2 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: RHB024 MIFTS: 58	Rhabdomyosarcoma 2 Categories: Genetic diseases, Rare diseases, Cancer diseases, Muscle diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Rhabdomyosarcoma 2

MalaCards integrated aliases for Rhabdomyosarcoma 2:

Name: Rhabdomyosarcoma 2 ⁵⁷ ⁷⁵

Alveolar Rhabdomyosarcoma ¹² ⁵³ ⁵⁹ ³⁷ ²⁹ ¹⁵ ⁷³

Rhabdomyosarcoma Alveolar ⁵³ ⁷⁵ ⁵⁵ ⁴⁰

Rhabdomyosarcoma, Alveolar ⁵⁷ ⁷⁶ ⁴⁴

Alveolar Childhood Rhabdomyosarcoma ¹² ⁷³

Rhabdomyosarcoma 2, Alveolar ⁵⁷ ¹³

Rms2 ⁵⁷ ⁷⁵

Rmsa ⁵⁷ ⁷⁵

Pediatric Alveolar Rhabdomyosarcoma ¹²

Rhabdomyosarcoma, Alveolar; Rmsa ⁵⁷

Arms ⁵³

Characteristics:

OMIM:

⁵⁷

Inheritance:
autosomal recessive

HPO:

³²

rhabdomyosarcoma 2:
Inheritance autosomal recessive inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Muscle diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of other connective and soft tissue

Malignant neoplasm: Connective and soft tissue, unspecified

External Ids:

OMIM ⁵⁷ 268220

Disease Ontology ¹² DOID:4051

MeSH ⁴⁴ D018232

NCIt ⁵⁰ C3749 C7958

SNOMED-CT ⁶⁸ 404053004 63449009

Orphanet ⁵⁹ ORPHA99756

UMLS via Orphanet ⁷⁴ C0206655

ICD10 via Orphanet ³⁴ C49.9

MESH via Orphanet ⁴⁵ D018232

MedGen ⁴² C0206655

KEGG ³⁷ H00037

SNOMED-CT via HPO ⁶⁹ 258211005

UMLS ⁷³ C0206655 C0279613

Sources

Summaries for Rhabdomyosarcoma 2

UniProtKB/Swiss-Prot : ⁷⁵ Rhabdomyosarcoma 2: A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas.

MalaCards based summary : Rhabdomyosarcoma 2, also known as alveolar rhabdomyosarcoma, is related to embryonal rhabdomyosarcoma and rhabdomyosarcoma. An important gene associated with Rhabdomyosarcoma 2 is PAX3 (Paired Box 3), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Pathways in cancer. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, skeletal muscle and lung, and related phenotypes are alveolar rhabdomyosarcoma and growth/size/body region

Wikipedia : ⁷⁶ Alveolar rhabdomyosarcoma (ARMS) is a sub-type of the rhabdomyosarcoma soft tissue cancer family whose... more...

Description from OMIM: 268220

Sources

Related Diseases for Rhabdomyosarcoma 2

Diseases in the Rhabdomyosarcoma family:

Rhabdomyosarcoma 2

Diseases related to Rhabdomyosarcoma 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)

#	Related Disease	Score	Top Affiliating Genes
1	embryonal rhabdomyosarcoma	26.5	CDK4 DES EWSR1 FOXO1 MB MYCN
2	rhabdomyosarcoma	24.7	ALK CDK4 DES ENO2 EWSR1 FOXO1
3	orbit alveolar rhabdomyosarcoma	11.1
4	ring chromosome 7	10.7	CDK4 MDM2
5	adrenal neuroblastoma	10.7	ENO2 MYCN
6	giant cell myocarditis	10.7	DES MB
7	cervical polyp	10.7	DES MYOD1
8	malignant triton tumor	10.7	DES MB
9	infiltrating angiolipoma	10.7	CDK4 MDM2
10	primitive neuroectodermal tumor of the cervix uteri	10.6	DES ENO2
11	cellular schwannoma	10.6	MDM2 PAX3 PAX7
12	sclerosing liposarcoma	10.6	MB MDM2
13	malignant ectomesenchymoma	10.6	DES ENO2
14	extraosseous osteosarcoma	10.6	CDK4 MDM2
15	inflammatory mfh	10.6	CDK4 MDM2
16	epulis	10.6	DES ENO2
17	ossifying fibromyxoid tumor	10.5	DES ENO2
18	orbit rhabdomyosarcoma	10.5	MB MYOG
19	pericardium cancer	10.5	ENO2 MB MYCN
20	spindle cell rhabdomyosarcoma	10.5	DES MB MYOD1
21	central nervous system mesenchymal non-meningothelial tumor	10.5	FOXO1 MYOD1 PAX3 PAX7
22	epithelioid leiomyosarcoma	10.5	DES ENO2
23	myofibroma	10.5	DES MB
24	ectomesenchymoma	10.5	DES ENO2 PAX3
25	bilateral retinoblastoma	10.5	DES MB MYCN
26	adult medulloblastoma	10.5	ENO2 MDM2 MYCN
27	childhood kidney cell carcinoma	10.5	ALK FOXO1 PAX3
28	mixed liposarcoma	10.5	CDK4 MB MDM2
29	kidney sarcoma	10.5	TH WT1
30	heart sarcoma	10.5	ENO2 MDM2 WT1
31	kidney clear cell sarcoma	10.5	TH WT1
32	sarcomatosis	10.5	EWSR1 WT1
33	lipoblastoma	10.5	CDK4 MDM2
34	neonatal hypoxic and ischemic brain injury	10.4	ENO2 TH
35	chondroid lipoma	10.4	CDK4 ENO2 MDM2
36	ovarian small cell carcinoma	10.4	DES WT1
37	small cell osteogenic sarcoma	10.4	ENO2 EWSR1
38	conventional central osteosarcoma	10.4	EWSR1 MDM2
39	glomangioma	10.4	DES ENO2 MB
40	ischemic fasciitis	10.4	CDK4 DES MDM2
41	dedifferentiated liposarcoma	10.4	CDK4 DES MDM2
42	epithelioid cell melanoma	10.4	ENO2 WT1
43	lipomatosis, multiple	10.4	CDK4 DES MDM2
44	orbital cancer	10.4	ENO2 EWSR1
45	conventional leiomyosarcoma	10.3	MYOD1 MYOG PAX7
46	botryoid rhabdomyosarcoma	10.3	DES MB MYOD1 PAX3
47	soft tissue sarcoma	10.3	EWSR1 FOXO1 MDM2
48	breast cancer	10.3
49	sarcoma, synovial	10.3	DES IGF1R MDM2
50	askin's tumor	10.2	ENO2 EWSR1 MYCN

Graphical network of the top 20 diseases related to Rhabdomyosarcoma 2:

Sources

Symptoms & Phenotypes for Rhabdomyosarcoma 2

Symptoms via clinical synopsis from OMIM:

⁵⁷

Oncology:
alveolar rhabdomyosarcoma

Clinical features from OMIM:

268220

Human phenotypes related to Rhabdomyosarcoma 2:

³²

#	Description	HPO Frequency	HPO Source Accession
1	alveolar rhabdomyosarcoma ³²		HP:0006779

MGI Mouse Phenotypes related to Rhabdomyosarcoma 2:

⁴⁶ (show all 21)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.41	ALK CDK4 ENO2 FOXO1 IGF1R KIDINS220
2	cellular	MP:0005384	10.4	CDK4 DES ENO2 FOXO1 IGF1R KIDINS220
3	behavior/neurological	MP:0005386	10.38	MDM2 MYCN MYOG PAX3 PAX7 TH
4	cardiovascular system	MP:0005385	10.37	MYOD1 PAX3 TH WT1 CDK4 DES
5	homeostasis/metabolism	MP:0005376	10.36	CDK4 DES FOXO1 ALK IGF1R MB
6	mortality/aging	MP:0010768	10.33	ALK CDK4 DES FOXO1 IGF1R KIDINS220
7	embryo	MP:0005380	10.26	CDK4 FOXO1 IGF1R MB MDM2 MYCN
8	hematopoietic system	MP:0005397	10.22	WT1 CDK4 FOXO1 IGF1R MB MDM2
9	muscle	MP:0005369	10.21	CDK4 DES FOXO1 IGF1R MB MDM2
10	endocrine/exocrine gland	MP:0005379	10.2	PAX3 PAX7 ALK CDK4 FOXO1 IGF1R
11	craniofacial	MP:0005382	10.12	ENO2 FOXO1 IGF1R MDM2 MYCN PAX3
12	digestive/alimentary	MP:0005381	10.11	CDK4 FOXO1 IGF1R MDM2 MYCN PAX3
13	integument	MP:0010771	10.1	ALK CDK4 FOXO1 IGF1R MDM2 MYOG
14	neoplasm	MP:0002006	10.1	ALK CDK4 FOXO1 IGF1R MDM2 MYOD1
15	liver/biliary system	MP:0005370	10.08	CDK4 FOXO1 IGF1R MDM2 MYCN PAX3
16	nervous system	MP:0003631	10.07	ALK CDK4 ENO2 IGF1R KIDINS220 MDM2
17	no phenotypic analysis	MP:0003012	10.02	MYOG PAX3 PAX7 FOXO1 KIDINS220 MDM2
18	normal	MP:0002873	9.96	CDK4 FOXO1 MDM2 MYCN MYOD1 MYOG
19	reproductive system	MP:0005389	9.76	ALK CDK4 FOXO1 IGF1R MDM2 MYCN
20	respiratory system	MP:0005388	9.7	IGF1R MB MYCN MYOD1 MYOG PAX3
21	skeleton	MP:0005390	9.28	ALK FOXO1 IGF1R MDM2 MYCN MYOD1

Sources

Drugs & Therapeutics for Rhabdomyosarcoma 2

Drugs for Rhabdomyosarcoma 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 3,Phase 2

41575-94-4

10339178 498142 38904

Cyclophosphamide

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

50-18-0, 6055-19-2

2907

Dactinomycin

Approved, Investigational

Phase 3,Phase 2

50-76-0

2019 457193

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Not Applicable

23214-92-8

31703

Etoposide

Approved

Phase 3,Phase 2,Not Applicable

33419-42-0

36462

Ifosfamide

Approved

Phase 3,Phase 2,Not Applicable

3778-73-2

3690

Morphine

Approved, Investigational

Phase 3,Phase 1,Phase 2

57-27-2

5288826

Topotecan

Approved, Investigational

Phase 3,Phase 2

119413-54-6, 123948-87-8

60700

Vincristine

Approved, Investigational

Phase 3,Phase 2,Not Applicable

2068-78-2, 57-22-7

5978

Vinorelbine

Approved, Investigational

Phase 3,Phase 2

71486-22-1

60780 44424639

Irinotecan

Approved, Investigational

Phase 3,Phase 2

97682-44-5, 100286-90-6

60838

Lenograstim

Approved, Investigational

Phase 3,Phase 2

135968-09-1

Epirubicin

Approved

Phase 3,Phase 2

56420-45-2

41867

Everolimus

Approved

Phase 3,Phase 2

159351-69-6

6442177

Miconazole

Approved, Investigational, Vet_approved

Phase 3,Phase 2

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 3,Phase 2

53123-88-9

5284616 6436030 46835353

Cyproheptadine

Approved

Phase 3

129-03-3

2913

Histamine

Approved, Investigational

Phase 3

75614-87-8, 51-45-6

774

Doxil

Approved June 1999

Phase 3,Phase 2,Not Applicable

31703

Camptothecin

Experimental

Phase 3,Phase 2

7689-03-4

Alkylating Agents

Phase 3,Phase 2,Not Applicable

Anti-Bacterial Agents

Phase 3,Phase 2,Not Applicable

Antibiotics, Antitubercular

Phase 3,Phase 2,Not Applicable

Anti-Infective Agents

Phase 3,Phase 2

Antimitotic Agents

Phase 3,Phase 2,Not Applicable

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Not Applicable

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Not Applicable

Antirheumatic Agents

Phase 3,Phase 2,Not Applicable

Etoposide phosphate

Phase 3,Phase 2,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Not Applicable

Isophosphamide mustard

Phase 3,Phase 2,Not Applicable

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

topoisomerase I inhibitors

Phase 3,Phase 2

Topoisomerase Inhibitors

Phase 3,Phase 2,Not Applicable

Adjuvants, Immunologic

Phase 3

Antifungal Agents

Phase 3,Phase 2

Dermatologic Agents

Phase 3,Phase 2

Anti-Allergic Agents

Phase 3

Antipruritics

Phase 3

Gastrointestinal Agents

Phase 3

Histamine Antagonists

Phase 3

Histamine H1 Antagonists

Phase 3

Histamine Phosphate

Phase 3

51-74-1

65513

Neurotransmitter Agents

Phase 3

Serotonin Agents

Phase 3

Serotonin Antagonists

Phase 3

Serotonin

Investigational, Nutraceutical

Phase 3

50-67-9

5202

Dacarbazine

Approved, Investigational

Phase 2

4342-03-4

5351166

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Interventional clinical trials:

(show all 35)

#	Name	Status	NCT ID	Phase	Drugs
1	Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma	Unknown status	NCT00379457	Phase 3	carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
2	Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma	Completed	NCT00354835	Phase 3	Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
3	Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma	Completed	NCT00003958	Phase 3	vincristine sulfate;cyclophosphamide;topotecan hydrochloride
4	Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma	Completed	NCT00002898	Phase 3	carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
5	Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma	Recruiting	NCT02567435	Phase 3	Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
6	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3	cyproheptadine hydrochloride
7	Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma	Completed	NCT01055314	Phase 2	Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
8	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma	Completed	NCT01222715	Phase 2	Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
9	A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas	Completed	NCT00001566	Phase 2	indinavir sulfate
10	Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma	Completed	NCT00025363	Phase 2	vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
11	Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma	Completed	NCT00923351	Phase 1, Phase 2	Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
12	Ixabepilone in Treating Young Patients With Refractory Solid Tumors	Completed	NCT00331643	Phase 2	ixabepilone
13	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma	Completed	NCT00003955	Phase 2	cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
14	Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas	Completed	NCT00003745	Phase 2	topotecan hydrochloride
15	Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma	Completed	NCT00031915	Phase 2	imatinib mesylate
16	Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors	Completed	NCT00025441	Phase 2	carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
17	Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer	Completed	NCT00002515	Phase 2	carboplatin;thiotepa;topotecan hydrochloride
18	Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma	Recruiting	NCT03041701	Phase 1, Phase 2	Dasatinib;Ganitumab
19	A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma	Recruiting	NCT02748135	Phase 1, Phase 2	TB-403 20mg/kg;TB-403 50mg/kg;TB-403 100mg/kg;TB-403 ≤175mg/kg
20	CREATE: Cross-tumoral Phase 2 With Crizotinib	Active, not recruiting	NCT01524926	Phase 2	Crizotinib (PF-02341066)
21	Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma	Active, not recruiting	NCT00077285	Phase 2	carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
22	Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features	Unknown status	NCT00314925	Phase 1	Seneca Valley Virus (biological agent)
23	Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma	Completed	NCT01609803
24	Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma	Completed	NCT01626170
25	Biomarkers in Patients With Advanced Rhabdomyosarcoma	Completed	NCT01668095
26	Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma	Completed	NCT01496573
27	Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma	Completed	NCT01585376
28	Protein Expression in Samples From Young Patients With Rhabdomyosarcoma	Completed	NCT01426945
29	Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma	Completed	NCT01365962
30	Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma	Completed	NCT01433237
31	DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma	Completed	NCT01419509
32	Combination Chemotherapy in Treating Patients With Sarcoma	Completed	NCT00662233	Not Applicable	cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
33	Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma	Recruiting	NCT03296371
34	Collecting and Storing Tissue From Young Patients With Cancer	Recruiting	NCT00898755
35	Risk Factors for Drusen Progression	Withdrawn	NCT01830608

Search NIH Clinical Center for Rhabdomyosarcoma 2

Cochrane evidence based reviews: rhabdomyosarcoma, alveolar

Sources

Genetic Tests for Rhabdomyosarcoma 2

Genetic tests related to Rhabdomyosarcoma 2:

#	Genetic test	Affiliating Genes
1	Alveolar Rhabdomyosarcoma ²⁹	FOXO1 PAX3 PAX7

Sources

Anatomical Context for Rhabdomyosarcoma 2

MalaCards organs/tissues related to Rhabdomyosarcoma 2:

⁴¹

Bone, Skeletal Muscle, Lung, Bone Marrow, Testes, T Cells, Liver

Sources

Publications for Rhabdomyosarcoma 2

Articles related to Rhabdomyosarcoma 2:

(show top 50) (show all 386)

#	Title	Authors	Year
1	Cytologic Diagnosis of Metastatic Alveolar Rhabdomyosarcoma in Cerebrospinal Fluid: A Case Report. ( 29902914 )	Shim B....Ryu H.S.	2018
2	Importance of whole-body imaging with complete coverage of hands and feet in alveolar rhabdomyosarcoma staging. ( 29368010 )	Scheer M....Von Kalle T.	2018
3	Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells. ( 29899822 )	Wolff D.W....Mal A.K.	2018
4	PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. ( 29367756 )	Hanna J.A....Hatley M.E.	2018
5	Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy. ( 28834127 )	Kinoshita M....Moritake H.	2017
6	Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity. ( 28875443 )	Thompson L.D.R....Bishop J.A.	2017
7	NFI_B signaling in alveolar rhabdomyosarcoma. ( 28883017 )	Cleary M.M....Keller C.	2017
8	Hypercalcaemia secondary to ectopic parathyroid hormone expression in an adolescent with metastatic alveolar rhabdomyosarcoma. ( 28843052 )	Brooks R....Gray J.C.	2017
9	The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells. ( 27572312 )	Jaaks P....Bernasconi M.	2016
10	Breast relapse after metastatic alveolar rhabdomyosarcoma: Is it an incurable entity? ( 27168712 )	Iniesta S.L....Menor C.E.	2016
11	P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma. ( 27453350 )	Bharathy N....Taneja R.	2016
12	Alveolar rhabdomyosarcoma of the sphenoid sinus mimicking optic neuritis presenting with intermittent visual loss in an adult. ( 27932889 )	Liu W....Lai T.Y.	2016
13	Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. ( 27760049 )	BAPhm M....SchAofer B.W.	2016
14	Decreased CDKN1C Expression in Congenital Alveolar Rhabdomyosarcoma Associated with Beckwith-Wiedemann Syndrome. ( 27345568 )	Piersigilli F....Danhaive O.	2016
15	Alveolar rhabdomyosarcoma of maxilla. ( 27194887 )	Ananthaneni A....Kiresur M.A.	2016
16	RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy. ( 27261335 )	Rengaswamy V....RAPssler J.	2016
17	Alveolar rhabdomyosarcoma masquerading as Burkitt's lymphoma in bone marrow. ( 25619947 )	Tailor I.K....Algwaiz L.	2015
18	DAX-1 Expression in Pediatric Rhabdomyosarcomas: Another Immunohistochemical Marker Useful in the Diagnosis of Translocation Positive Alveolar Rhabdomyosarcoma. ( 26168243 )	Virgone C....Alaggio R.	2015
19	Alveolar rhabdomyosarcoma of nasopharynx and paranasal sinuses with metastasis to breast in a middle-aged woman: a case report and literature review. ( 26823887 )	Liu H....Lu Y.	2015
20	Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease. ( 25659124 )	Lagutina I.V....Grosveld G.C.	2015
21	Primary alveolar rhabdomyosarcoma of fallopian tube masquerading as a unilateral adnexal mass: A case report and literature review. ( 26549082 )	Shahin N.A....Zheng W.	2015
22	Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. ( 26071485 )	Kephart J.J....Linardic C.M.	2015
23	Alveolar rhabdomyosarcoma on the left maxillary alveolus: a unique presentation. ( 25859531 )	Sudhakar S....Kiran C.h.S.	2015
24	Aggressive, solid variant of alveolar rhabdomyosarcoma with cutaneous involvement in a juvenile labrador retriever. ( 25555631 )	Otrocka-Domagala I....Mikolajczyk A.	2015
25	Alveolar rhabdomyosarcoma of the lip in an adult with clear cell features. ( 25812664 )	Seok J.Y....Chung D.H.	2015
26	Alveolar rhabdomyosarcoma with massive disseminated intravascular coagulopathy treated with systemic chemotherapy. ( 26770227 )	Yoon B.G....Kook H.	2015
27	Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma. ( 25790258 )	Woods G.M....Houghton P.J.	2015
28	Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options. ( 25821947 )	Loupe J.M....Hollenbach A.D.	2015
29	Alveolar rhabdomyosarcoma causing acute compartment syndrome of the forearm: a case report and review of the literature. ( 25414558 )	Valone F....Lattanza L.L.	2014
30	Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. ( 24334454 )	Crose L.E....Linardic C.M.	2014
31	Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcomas. ( 24641407 )	Liu C.X....Li F.	2014
32	The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas. ( 24173021 )	Schneider G....Ratajczak M.Z.	2014
33	A Study of Alveolar Rhabdomyosarcoma Copy Number Alterations by Single Nucleotide Polymorphism Analysis. ( 24569785 )	Lynn M....O'Sullivan M.	2014
34	PDGFRI^ reverses EphB4 signaling in alveolar rhabdomyosarcoma. ( 24733895 )	Aslam M.I....Keller C.	2014
35	Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. ( 25313138 )	Huertas-MartA-nez J....Tirado O.M.	2014
36	Lymphadenopathic form of solid variant of alveolar rhabdomyosarcoma: A rare case report. ( 25538389 )	Sharma T....Sharma S.P.	2014
37	State of the art in oncology: high risk neuroblastoma, alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and POST-TEXT 3 and 4 hepatoblastoma. ( 24528957 )	La Quaglia M.P.	2014
38	Alveolar Rhabdomyosarcoma Masquerading as Embryonal Subtype: The Value of Modern Molecular Diagnostic Testing. ( 24608324 )	Eftekhari K....Katowitz J.A.	2014
39	Successful in vivo tumor visualization using fluorescence laparoscopy in a mouse model of disseminated alveolar rhabdomyosarcoma. ( 25149634 )	Urla C....Seitz G.	2014
40	Glycogen synthase kinase 3I^ represses MYOGENIN function in alveolar rhabdomyosarcoma. ( 24577092 )	Dionyssiou M.G....McDermott J.C.	2014
41	A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis. ( 24614150 )	Lynn M....O'Sullivan M.	2014
42	Unilateral breast metastasis from alveolar rhabdomyosarcoma in adult detected by (18)F-FDG PET/CT. ( 25053243 )	CA!rdenas-Perilla R....Castell-Conesa J.	2014
43	A Leukemic Presentation of Alveolar Rhabdomyosarcoma in a 52-Year-Old Woman Without an Identifiable Primary Tumor. ( 25305220 )	Kern J.B....Duffield A.S.	2014
44	Cytologic diagnosis of metastatic alveolar rhabdomyosarcoma to the thyroid gland by fine-needle aspiration. ( 24513670 )	Walavalkar V....Owens C.L.	2014
45	Adult alveolar rhabdomyosarcoma of the lacrimal sac. ( 25207922 )	Neffendorf J.E....Pearson A.R.	2014
46	Fine-needle aspiration biopsy of alveolar rhabdomyosarcoma of stensen's duct: A case report and review of the literature. ( 24599626 )	Nunez A.L....Fatima H.	2014
47	FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. ( 24550147 )	Wachtel M....SchAofer B.W.	2014
48	FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. ( 24787670 )	Singh M....Houghton P.J.	2014
49	GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. ( 25432075 )	Srivastava R.K....Athar M.	2014
50	PLK1 phosphorylates PAX3-FOXO1 the inhibition of which triggers regression of alveolar rhabdomyosarcoma. ( 25398439 )	Thalhammer V....SchAofer B.W.	2014

Sources

Genes for Rhabdomyosarcoma 2

Genes related to Rhabdomyosarcoma 2 (3 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	PAX3	Paired Box 3	Protein Coding	988.84	Molecular basis known ⁵⁷ Gene fusion ⁵⁹ Genetic Tests ²⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders (show sections)	9973247 8098985 11171995 (more) 8275086 7630639 9858583 8643596 11164187 15184910 16140913 11735247 11863357 10439042 10616906 9570138 19199574 18414034 9294613 8221646 10521655 9479491 7862145 15602708 15313887 17954266 10700864 9169092 7624119 8875708 8889501
2	FOXO1	Forkhead Box O1	Protein Coding	988.15	Molecular basis known ⁵⁷ Gene fusion ⁵⁹ Genetic Tests ²⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders (show sections)	11171995 7630639 8875708 (more) 8889501 9546061 19704258 7624119 8634710 8643596 9479491 11735247 10700864 15184910 18303411 16140913 9294613 9570138 10616906
3	PAX7	Paired Box 7	Protein Coding	987.37	Molecular basis known ⁵⁷ Gene fusion ⁵⁹ Genetic Tests ²⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders (show sections)	9973247 10700864 8889501 (more) 17954266 15313887 9570138 10439042 9339373 9479491
4	MYOD1	Myogenic Differentiation 1	Protein Coding	24.7	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9256013
5	MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	Protein Coding	24.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	12880971 9872655 2323837
6	MB	Myoglobin	Protein Coding	21.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	2119961
7	MDM2	MDM2 Proto-Oncogene	Protein Coding	21.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15024701 8751388 19707204
8	WT1	Wilms Tumor 1	Protein Coding	21.26	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9841704
9	ENO2	Enolase 2	Protein Coding	20.04	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	2119961
10	CDK4	Cyclin Dependent Kinase 4	Protein Coding	19.96	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15024701
11	DES	Desmin	Protein Coding	19.73	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	18727437 2119961 18705836
12	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	19.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	8083365 9052994
13	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	17.92	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	12405914
14	TH	Tyrosine Hydroxylase	Protein Coding	17.86	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	10393831 18057715
15	MYOG	Myogenin	Protein Coding	17.65	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	10666368 18727437 18540440 (more) 18705836
16	KIDINS220	Kinase D Interacting Substrate 220	Protein Coding	17.46	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
17	RHD	Rh Blood Group D Antigen	Protein Coding	17.22	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
18	RMST	Rhabdomyosarcoma 2 Associated Transcript	RNA Gene	16.87	GeneCards inferred via : Gene name Transcripts (show sections)
19	EWSR1	EWS RNA Binding Protein 1	Protein Coding	16.3	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Rhabdomyosarcoma 2

Cosmic variations for Rhabdomyosarcoma 2:

⁹

(show top 50) (show all 177)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM45256	TP53	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.871A>C	p.K291Q	17:7673749-7673749	28
2	COSM44536	TP53	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.728T>C	p.M243T	17:7674235-7674235	28
3	COSM45253	TP53	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.611A>G	p.E204G	17:7674920-7674920	28
4	COSM766	PIK3CA	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.1636C>A	p.Q546K	3:179218306-179218306	28
5	COSM760	PIK3CA	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.1624G>A	p.E542K	3:179218294-179218294	28
6	COSM532	KRAS	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.38G>A	p.G13D	12:25245347-25245347	28
7	COSM1042370	EIF4A2	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.854A>G	p.K285R	3:186787209-186787209	28
8	COSM6909274	DOT1L	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.1826T>A	p.L609Q	19:2214499-2214499	28
9	COSM12475	CDKN2A	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.238C>T	p.R80*	9:21971121-21971121	28
10	COSM6948085	APC	soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.2335T>G	p.L779V	5:112837929-112837929	28
11	COSM6909273		soft tissue,striated muscle,rhabdomyosarcoma,alveolar	c.1826T>A	p.L609Q	19:2214499-2214499	28
12	COSM10648	TP53	soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic	c.524G>A	p.R175H	17:7675088-7675088	16
13	COSM45005	TP53	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.739A>G	p.N247D	17:7674224-7674224	16
14	COSM11081	TP53	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.733G>T	p.G245C	17:7674230-7674230	16
15	COSM10662	TP53	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.743G>A	p.R248Q	17:7674220-7674220	16
16	COSM10654	TP53	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.637C>T	p.R213*	17:7674894-7674894	16
17	COSM44720	TP53	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.961A>T	p.K321*	17:7673567-7673567	16
18	COSM6932	TP53	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.733G>A	p.G245S	17:7674230-7674230	16
19	COSM10725	TP53	soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic	c.701A>G	p.Y234C	17:7674262-7674262	16
20	COSM45255	TP53	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.668C>G	p.P223R	17:7674863-7674863	16
21	COSM6986214	SOX9	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.76A>G	p.M26V	17:72121467-72121467	16
22	COSM6945139	RICTOR	soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic	c.2898-1G>T	p.?	5:38952426-38952426	16
23	COSM6986215	PTPRT	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.2277G>T	p.Q759H	20:42248779-42248779	16
24	COSM13016	PTPN11	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.226G>C	p.E76Q	12:112450406-112450406	16
25	COSM14271	PTPN11	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.1508G>T	p.G503V	12:112489084-112489084	16
26	COSM13014	PTPN11	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.214G>A	p.A72T	12:112450394-112450394	16
27	COSM13013	PTPN11	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.205G>A	p.E69K	12:112450385-112450385	16
28	COSM6986208	PTCH1	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.208G>A	p.A70T	9:95506593-95506593	16
29	COSM6910708	POLE	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.5975G>C	p.C1992S	12:132634215-132634215	16
30	COSM1083818	PIK3CG	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.2638G>A	p.E880K	7:106883041-106883041	16
31	COSM763	PIK3CA	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.1633G>A	p.E545K	3:179218303-179218303	16
32	COSM775	PIK3CA	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.3140A>G	p.H1047R	3:179234297-179234297	16
33	COSM6914067	PDGFRA	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.3195G>C	p.E1065D	4:54295197-54295197	16
34	COSM6964921	NTRK3	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.492C>A	p.C164*	15:88137534-88137534	16
35	COSM580	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.181C>A	p.Q61K	1:114713909-114713909	16
36	COSM585	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.183A>T	p.Q61H	1:114713907-114713907	16
37	COSM564	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.35G>A	p.G12D	1:114716126-114716126	16
38	COSM569	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.37G>C	p.G13R	1:114716124-114716124	16
39	COSM584	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.182A>G	p.Q61R	1:114713908-114713908	16
40	COSM563	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.34G>A	p.G12S	1:114716127-114716127	16
41	COSM574	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.38G>T	p.G13V	1:114716123-114716123	16
42	COSM562	NRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.34G>T	p.G12C	1:114716127-114716127	16
43	COSM6910706	NOTCH1	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.3277T>C	p.Y1093H	9:136508280-136508280	16
44	COSM6933086	NF1	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.7870G>C	p.A2624P	17:31357269-31357269	16
45	COSM516	KRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.34G>T	p.G12C	12:25245351-25245351	16
46	COSM522	KRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.35G>C	p.G12A	12:25245350-25245350	16
47	COSM553	KRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.182A>T	p.Q61L	12:25227342-25227342	16
48	COSM6930430	KMT2D	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.1291G>T	p.E431*	12:49052392-49052392	16
49	COSM2965310	KDM6A	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.493C>T	p.R165*	23:45020659-45020659	16
50	COSM486	HRAS	soft tissue,striated muscle,rhabdomyosarcoma,embryonal	c.37G>C	p.G13R	11:534286-534286	16

Copy number variations for Rhabdomyosarcoma 2 from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	25460	1	18957499	19075360	Amplification	PAX7	Alveolar rhabdomyosarcoma
2	76221	13	28900000	50900000	Amplification	FOXO1A	Alveolar rhabdomyosarcoma
3	141698	2	215300000	221500000	Amplification	PAX3	Alveolar rhabdomyosarcoma

Sources

Expression for Rhabdomyosarcoma 2

Search GEO for disease gene expression data for Rhabdomyosarcoma 2.

Sources

Pathways for Rhabdomyosarcoma 2

Pathways related to Rhabdomyosarcoma 2 according to KEGG:

³⁷

#	Name	Kegg Source Accession
1	Transcriptional misregulation in cancer	hsa05202

Pathways related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁷	12.52	ALK CDK4 FOXO1 IGF1R MDM2
2	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.39	ALK CDK4 FOXO1 IGF1R MDM2
3	AKT Signaling Pathway ⁶⁷	11.71	CDK4 FOXO1 IGF1R MDM2
4	Transcriptional misregulation in cancer ³⁷	11.49	EWSR1 FOXO1 IGF1R MDM2 MYCN PAX3
5	Regulation of nuclear SMAD2/3 signaling ¹	11.43	CDK4 FOXO1 MYOD1
6	Glioblastoma Multiforme ⁶⁴	11.3	CDK4 FOXO1 IGF1R MDM2
7	Regulation of retinoblastoma protein ¹	11.08	MDM2 MYOD1 PAX3

Sources

GO Terms for Rhabdomyosarcoma 2

Biological processes related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	9.91	FOXO1 MYCN MYOD1 MYOG PAX3 PAX7
2	heart development	GO:0007507	9.83	MB MDM2 TH WT1
3	regulation of gene expression	GO:0010468	9.81	CDK4 MDM2 MYOD1 PAX7
4	positive regulation of transcription, DNA-templated	GO:0045893	9.73	FOXO1 MYCN MYOD1 MYOG PAX3 WT1
5	cellular response to growth factor stimulus	GO:0071363	9.61	MDM2 MYOG TH
6	positive regulation of myoblast fusion	GO:1901741	9.55	MYOD1 MYOG
7	myotube differentiation	GO:0014902	9.54	MYOD1 MYOG
8	skeletal muscle tissue development	GO:0007519	9.5	MYOD1 MYOG PAX7
9	cellular response to alkaloid	GO:0071312	9.49	MDM2 TH
10	positive regulation of skeletal muscle fiber development	GO:0048743	9.48	MYOD1 MYOG
11	negative regulation of apoptotic process	GO:0043066	9.43	ALK FOXO1 IGF1R MDM2 PAX7 WT1
12	muscle cell fate commitment	GO:0042693	9.4	MYOD1 MYOG
13	response to ether	GO:0045472	9.16	MDM2 TH
14	muscle organ development	GO:0007517	8.92	MYOD1 MYOG PAX3 PAX7
15	multicellular organism development	GO:0007275	10	ALK CDK4 IGF1R MYOD1 MYOG PAX3

Molecular functions related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RNA polymerase II transcription factor activity, sequence-specific DNA binding	GO:0000981	9.7	FOXO1 MYCN MYOD1 MYOG PAX3 PAX7
2	DNA binding transcription factor activity	GO:0003700	9.5	FOXO1 MYCN MYOD1 MYOG PAX3 PAX7
3	sequence-specific DNA binding	GO:0043565	9.1	FOXO1 MYOD1 MYOG PAX3 PAX7 WT1

Sources

Sources for Rhabdomyosarcoma 2

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia